Applied Therapeutics, Inc.

Frontier Communications Parent, Inc.

Applied Therapeutics Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses (APLT)

Shareholder rights law firm Johnson Fistel, LLP is investigating whether Applied Therapeutics, Inc. (NASDAQ: APLT) or any of its executive officers violated securities laws by misrepresenting or failing to timely disclose information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.

What if I purchased Symbotic securities? If you purchased securities and suffered losses on your investment, join our investigation now:

If you suffered a loss on your investment and would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. The information provided will be held in strict confidence unless and until you authorize us to disclose it.

Name(Required)

First Last

Email(Required)

Phone(Required)

Estimated range of Losses(Required)

Where did you see our press release?(Required)

If you selected 'Other' above, please specify below:(Required)

Would you like to receive future case and securities updates from Johnson Fistel, LLP via email?(Required)

Yes

Would you like to receive information about Johnson Fistel, LLP's free portfolio monitoring service?(Required)

Yes

By checking the box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Johnson Fistel, LLP, and that submission to or receipt of information from the firm or one of its attorneys via this form, website, email, or telephone does not create an attorney-client relationship.(Required)

I Agree

Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.

There is no cost or obligation to you.

What is Johnson Fistel Investigating? On November 27, 2024, Applied Therapeutics publicly disclosed that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) concerning the New Drug Application (NDA) for govorestat, a novel central nervous system (CNS)-penetrant aldose reductase inhibitor developed for the treatment of Classic Galactosemia. The company stated that the CRL reflects the FDA’s conclusion that the NDA could not be approved in its current state, with specific deficiencies identified in the clinical application.

Following this news Applied Therapeutics’ stock price plummeted by over 70% during early morning trading on November 29, 2024.

What if I have relevant nonpublic information? Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program. Under the SEC program, whistleblowers who provide original information may, under certain circumstances, receive rewards totaling up to thirty percent of any successful recovery made by the SEC. For more information, contact Jim Baker at (619) 814-4471 or jimb@johnsonfistel.com.